- PR Newswire•2 hours ago
INDIANAPOLIS, Sept. 26, 2016 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the CoaguChek XS mPOC app for use with the CoaguChek XS meter. The new app makes the Bluetooth-enabled ...
- Market Realist•6 days ago
According to Bloomberg’s consensus, ~75% of the analysts recommend a “buy” for Roche (RHHBY), and 25% of the analysts recommend a “hold.”
- Market Realist•10 days ago
Roche (RHHBY) noted that Tecentriq was granted Breakthrough therapy designation for use in the treatment of NSCLC.
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||31.27 - 31.41|
|52wk Range||29.89 - 35.13|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||23.32|
|Avg Vol (3m)||929,984|
|Dividend & Yield||1.02 (3.23%)|